Arrevus, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.arrevus.com
Clinical Trials
6
Active:1
Completed:4
Trial Phases
2 Phases
Phase 2:5
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (83.3%)Phase 3
1 (16.7%)Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients
Phase 2
Completed
- Conditions
- Melioidosis
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Arrevus Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT05105035
- Locations
- 🇹🇭
Maharat Nakhonratchasima Hospital, Nai Muang, Thailand
🇹🇭Srinagarind Hospital, Khon Kaen University, Nai Muang, Thailand
🇹🇭Sunpasitthiprasong Hospital, Nai Muang, Thailand
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase 3
Completed
- Conditions
- Acute Bacterial Skin and Skin Structure Infections
- Interventions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Arrevus Inc.
- Target Recruit Count
- 716
- Registration Number
- NCT02570490
Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Arrevus Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02569541
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
Phase 2
Terminated
- Conditions
- Prosthetic Joint Infections of KneeInfected SpacersProsthetic Joint Infections of Hip
- Interventions
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Arrevus Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01756924
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Arrevus Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00948142
News
No news found